Astellas Pharma Inc. (ALPMF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Astellas Pharma Inc. (ALPMF) with AI Score 58/100 (Hold). Astellas Pharma Inc. is a global pharmaceutical company focused on developing and marketing innovative medicines across various therapeutic areas. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Astellas Pharma Inc. (ALPMF) Healthcare & Pipeline Overview
Astellas Pharma Inc. is a global pharmaceutical company specializing in prescription pharmaceuticals across key therapeutic areas like oncology, urology, and immunology. With a focus on innovation and strategic collaborations, Astellas develops and commercializes drugs such as XTANDI and PADCEV, maintaining a significant presence in the competitive pharmaceutical landscape.
Investment Thesis
Astellas Pharma Inc. presents a compelling investment thesis based on its diverse product portfolio and strategic collaborations. With a P/E ratio of 12.95 and a profit margin of 15.7%, the company demonstrates financial stability. Key growth drivers include the continued expansion of XTANDI in prostate cancer treatment and the uptake of PADCEV in urothelial cancer. The company's dividend yield of 3.26% offers an attractive return for investors. However, potential risks include patent expirations and competition from biosimilars. Astellas's strategic research alliances, such as the one with Harvard University, position it for long-term innovation and growth.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $29.34 billion reflects Astellas's significant presence in the pharmaceutical industry.
- P/E ratio of 12.95 indicates a reasonable valuation compared to its earnings.
- Gross margin of 77.7% demonstrates strong pricing power and efficient cost management.
- Dividend yield of 3.26% provides an attractive income stream for investors.
- Beta of 0.12 suggests low volatility compared to the broader market.
Competitors & Peers
Strengths
- Diverse product portfolio across multiple therapeutic areas.
- Strong research and development capabilities.
- Strategic collaborations with leading research institutions.
- Global presence and established distribution network.
Weaknesses
- Reliance on key products like XTANDI.
- Exposure to patent expirations and generic competition.
- Dependence on regulatory approvals for new drugs.
- Limited presence in emerging markets compared to some competitors.
Catalysts
- Ongoing: Continued expansion of XTANDI in prostate cancer treatment.
- Ongoing: Uptake of PADCEV in urothelial cancer.
- Upcoming: Results from ongoing clinical trials for new therapies.
- Ongoing: Strategic collaborations with research institutions.
- Ongoing: Geographic expansion into emerging markets.
Risks
- Potential: Patent expirations on key drugs.
- Potential: Competition from generic and biosimilar drugs.
- Potential: Regulatory setbacks and delays in drug approvals.
- Potential: Product liability claims and litigation risks.
- Ongoing: Economic downturns affecting healthcare spending.
Growth Opportunities
- Expansion of XTANDI: XTANDI, an androgen receptor signaling inhibitor for prostate cancer, presents a significant growth opportunity. The global prostate cancer market is projected to reach $12 billion by 2028. Astellas can capitalize on this by expanding XTANDI's indications and geographic reach. The company's ongoing clinical trials and marketing efforts will be crucial in driving future growth.
- Uptake of PADCEV: PADCEV, a treatment for urothelial cancer, offers another growth avenue. The urothelial cancer market is expected to grow as the global population ages. Astellas can increase PADCEV's market share through strategic partnerships and clinical trial advancements. The company's focus on addressing unmet needs in cancer treatment positions it well for future expansion.
- Strategic Collaborations: Astellas's strategic collaborations, such as the one with Harvard University, provide access to innovative technologies and therapeutic approaches. These collaborations can lead to the development of new drugs and therapies, driving long-term growth. The company's ability to identify and partner with leading research institutions will be critical in maintaining its competitive edge.
- Geographic Expansion: Expanding into emerging markets represents a significant growth opportunity for Astellas. These markets offer high growth potential due to increasing healthcare spending and unmet medical needs. Astellas can leverage its existing product portfolio and establish strategic partnerships to penetrate these markets. The company's focus on globalization will be essential in driving future revenue growth.
- Development of Cell Therapies: The strategic collaboration and license agreement with Minovia Therapeutics Ltd. for cell therapy programs targeting mitochondrial dysfunction presents a novel growth opportunity. As cell therapies gain traction in treating various diseases, Astellas's investment in this area could yield significant returns. This collaboration allows Astellas to explore innovative treatment modalities and expand its therapeutic offerings.
Opportunities
- Expansion into new therapeutic areas, such as cell therapies.
- Growth in emerging markets with increasing healthcare spending.
- Development of personalized medicine and targeted therapies.
- Strategic acquisitions to expand product portfolio and market reach.
Threats
- Increasing competition from generic and biosimilar drugs.
- Stringent regulatory requirements and potential delays in drug approvals.
- Economic downturns affecting healthcare spending.
- Product liability claims and litigation risks.
Competitive Advantages
- Patent protection for key drugs like XTANDI.
- Strong brand reputation and established market presence.
- Strategic collaborations with leading research institutions.
- Specialized expertise in key therapeutic areas.
About ALPMF
Founded in 1923 and headquartered in Tokyo, Japan, Astellas Pharma Inc. has evolved into a global pharmaceutical leader. The company engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas's product portfolio includes XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia; PADCEV, a treatment for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for overactive bladder; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, immunosuppressants used post-transplant. The company also offers treatments like mirabegron for neurogenic detrusor overactivity in pediatric patients, Vesicare for OAB treatment, Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, and Funguard/MYCAMINE, an antifungal agent. Astellas has established strategic collaborations with companies like Merck & Co., Inc., CytomX Therapeutics, Inc., and BANDAI NAMCO Entertainment Inc. to expand its research and development efforts. These collaborations enable Astellas to explore new therapeutic areas and technologies, reinforcing its commitment to addressing unmet medical needs.
What They Do
- Develops and commercializes prescription pharmaceuticals.
- Focuses on therapeutic areas such as oncology, urology, and immunology.
- Manufactures and markets drugs like XTANDI for prostate cancer.
- Offers treatments for overactive bladder, including Betanis/Myrbetriq/BETMIGA.
- Provides immunosuppressants like Prograf and Advagraf/Graceptor/ASTAGRAF for transplant patients.
- Engages in strategic collaborations to expand research and development efforts.
Business Model
- Develops and patents innovative pharmaceutical products.
- Conducts clinical trials to demonstrate safety and efficacy.
- Markets and sells prescription drugs through a global distribution network.
- Collaborates with other companies and research institutions to expand its product pipeline.
Industry Context
Astellas Pharma Inc. operates in the global pharmaceutical industry, characterized by intense competition, stringent regulatory requirements, and continuous innovation. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. Astellas competes with major pharmaceutical companies, including BMXXY (Bayer AG) and CHJTF (Chugai Pharmaceutical Co.), focusing on specialized therapeutic areas. The industry is witnessing a shift towards personalized medicine and targeted therapies, requiring companies to invest heavily in research and development.
Key Customers
- Patients requiring prescription medications.
- Hospitals and clinics.
- Pharmacies.
- Healthcare providers.
Financials
Chart & Info
Astellas Pharma Inc. (ALPMF) stock price: Price data unavailable
Latest News
-
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
Yahoo! Finance: ALPMF News · Mar 25, 2026
-
Pfizer aims for wider use of PARP drug in prostate cancer with new data
Yahoo! Finance: ALPMF News · Mar 19, 2026
-
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
Yahoo! Finance: ALPMF News · Mar 6, 2026
-
Pfizer Bladder Cancer Trial Results Deepen Oncology Growth And Risk Debate
Yahoo! Finance: ALPMF News · Mar 5, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALPMF.
Price Targets
Wall Street price target analysis for ALPMF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ALPMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
Pfizer aims for wider use of PARP drug in prostate cancer with new data
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
Pfizer Bladder Cancer Trial Results Deepen Oncology Growth And Risk Debate
Leadership: Naoki Okamura
CEO
Naoki Okamura serves as the CEO of Astellas Pharma Inc., leading a global workforce of 14,754 employees. His career spans several decades in the pharmaceutical industry, with a focus on strategic planning and business development. Okamura has held various leadership positions within Astellas, contributing to the company's growth and expansion. He is known for his expertise in navigating the complex regulatory landscape and fostering innovation within the organization.
Track Record: Under Naoki Okamura's leadership, Astellas Pharma Inc. has focused on strategic collaborations and expanding its product portfolio. Key achievements include the continued growth of XTANDI in prostate cancer treatment and the advancement of new therapies through strategic research alliances. Okamura has also overseen the company's efforts to penetrate emerging markets and develop personalized medicine approaches.
ALPMF OTC Market Information
The OTC Other tier, where ALPMF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial reporting requirements, making it difficult for investors to assess their financial health and operational performance. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks do not have to meet minimum listing standards, resulting in higher risks for investors. The OTC Other tier includes a wide range of companies, from early-stage startups to distressed or defunct businesses.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial transparency due to minimal reporting requirements.
- Higher potential for fraud and manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility.
- Risk of delisting or going dark.
- Verify the company's registration and regulatory filings.
- Review the company's business model and revenue sources.
- Assess the company's management team and their track record.
- Analyze the company's financial statements, if available.
- Check for any legal or regulatory issues.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Astellas Pharma Inc. is a well-established pharmaceutical company with a global presence.
- The company has a diverse product portfolio and strategic collaborations with reputable institutions.
- Astellas Pharma Inc. has a history of developing and commercializing innovative pharmaceutical products.
Common Questions About ALPMF
What does Astellas Pharma Inc. do?
Astellas Pharma Inc. is a global pharmaceutical company that develops, manufactures, and markets prescription drugs across various therapeutic areas, including oncology, urology, and immunology. The company's key products include XTANDI for prostate cancer, PADCEV for urothelial cancer, and Betanis/Myrbetriq/BETMIGA for overactive bladder. Astellas focuses on innovation and strategic collaborations to address unmet medical needs and improve patient outcomes. The company operates globally, with a significant presence in Japan, the United States, and Europe.
What do analysts say about ALPMF stock?
Analyst consensus on ALPMF stock is pending AI analysis. Key valuation metrics include a P/E ratio of 12.95 and a dividend yield of 3.26%. Growth considerations include the continued expansion of XTANDI and PADCEV, as well as strategic collaborations and geographic expansion. Investors should conduct their own research and consider their individual risk tolerance before making any investment decisions. No buy or sell recommendations are made here.
What are the main risks for ALPMF?
The main risks for Astellas Pharma Inc. include patent expirations on key drugs, competition from generic and biosimilar drugs, regulatory setbacks and delays in drug approvals, product liability claims, and economic downturns affecting healthcare spending. The company's reliance on key products like XTANDI exposes it to potential revenue declines if generic versions become available. Regulatory risks include the potential for delays or rejections of new drug applications. Economic risks include the impact of economic downturns on healthcare spending and demand for pharmaceutical products.
How does Astellas Pharma Inc. manage patent expiration risks?
Astellas Pharma Inc. manages patent expiration risks through a combination of strategies, including developing new formulations and indications for existing drugs, pursuing patent extensions, and investing in research and development to create new innovative products. The company also focuses on lifecycle management strategies to extend the market exclusivity of its key products. By diversifying its product portfolio and investing in innovation, Astellas aims to mitigate the impact of patent expirations on its revenue and profitability.
What are the key growth opportunities for ALPMF in healthcare?
Key growth opportunities for Astellas Pharma Inc. in healthcare include expanding into new therapeutic areas, such as cell therapies, and geographic markets, particularly emerging economies. The company's strategic collaboration with Minovia Therapeutics Ltd. for cell therapy programs targeting mitochondrial dysfunction presents a novel growth opportunity. Additionally, Astellas can capitalize on the increasing healthcare spending in emerging markets by expanding its presence and product offerings in these regions. The company's focus on personalized medicine and targeted therapies also positions it well for future growth.
What are the key factors to evaluate for ALPMF?
Astellas Pharma Inc. (ALPMF) currently holds an AI score of 58/100, indicating moderate score. Key strength: Diverse product portfolio across multiple therapeutic areas.. Primary risk to monitor: Potential: Patent expirations on key drugs.. This is not financial advice.
How frequently does ALPMF data refresh on this page?
ALPMF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALPMF's recent stock price performance?
Recent price movement in Astellas Pharma Inc. (ALPMF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse product portfolio across multiple therapeutic areas.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending and may provide additional insights.